Dialysis

The National Kidney Foundation Urges Passage of New Home Dialysis Bill

Retrieved on: 
Tuesday, April 23, 2024
Education, Congress, Patient, National Kidney Foundation, Kidney, Transplant, Travel, Disability, Health, House, Employment, Kidney disease, Senate, Renal replacement therapy, Nursing, ESKD, Legislation, Dialysis, Earl Blumenauer, Crash, Quality of life, NKF

WASHINGTON, April 23, 2024 /PRNewswire/ -- The National Kidney Foundation is applauding a move by Congress to increase access to care and improve outcomes for some patients on dialysis. The Improving Access to Home Dialysis Act (HR-8075) was introduced today in the U.S. House of Representatives by Reps. Carol Miller (R-WV), Marilyn Strickland (D-WA), Earl Blumenauer (D-OR), and Mariannette Miller-Meeks (R-IA). A companion bill is expected to be introduced soon in the Senate.

Key Points: 
  • WASHINGTON, April 23, 2024 /PRNewswire/ -- The National Kidney Foundation is applauding a move by Congress to increase access to care and improve outcomes for some patients on dialysis.
  • Home dialysis is a form of renal (kidney) replacement therapy (aka, dialysis) that can be done at home by the patient alone or with the help of a care partner.
  • "Patients deserve to know about all options for dialysis so they can make an educated choice for themselves," said Kevin Longino, Chief Executive Officer of the National Kidney Foundation and a kidney transplant recipient.
  • "Policies like this make me increasingly optimistic that more kidney patients struggling with dialysis can have a chance to get some of their life back."

DaVita's Global Operations Powered by 100% Renewable Energy

Retrieved on: 
Monday, April 22, 2024
Carbon, Climate change, Social, DaVita Inc., Solar energy, Security (finance), CDP, Electricity, Professional, Water, White, Environment, Risk, LED, Dialysis, ESG, Form 10-K, PPA, Renewable energy

DENVER, April 22, 2024  /PRNewswire/ -- By 2025, DaVita (NYSE: DVA), a leading provider of kidney care services, expects to match 100% of its electricity use across its global operations with renewable energy purchases. DaVita has contracted with ACCIONA Energía on a virtual power purchase agreement (PPA) facilitating the development of clean energy projects in Spain. This announcement follows DaVita reaching 100% renewable in its North American operations in December 2021. 

Key Points: 
  • DENVER, April 22, 2024 /PRNewswire/ -- By 2025, DaVita (NYSE: DVA), a leading provider of kidney care services, expects to match 100% of its electricity use across its global operations with renewable energy purchases.
  • "Expanding our renewable commitment across our global operations accelerates momentum and accountability to help mitigate the lasting impacts of climate change."
  • "With long-term PPAs such as this one, we accompany our customers through their decarbonization journey, enhancing sustainability in their operations and helping them reach their renewable energy goals."
  • To learn more about DaVita's global renewable energy commitment and other ESG focus areas, visit the ESG Reporting Hub .

Health Equity in Transplantation Coalition Demands to Know Why Expert Physicians' Advice Was Ignored in Medicare Cuts for Life-Saving Blood Tests for Transplant Patients

Retrieved on: 
Monday, April 22, 2024
Pain, CMS, Fox News, Kidney, Risk, The Wall Street Journal, Travel, Cover-up, Health, Heart, Transplant, Coalition, Life, FOIA, Congressional Black Caucus, Federation, Griot, Oportunidades, Science, MAC, USA Today, Patient, Politics, Physician, Dialysis, Kimberley Strassel, Health equity, Medicare, Freedom, Biopsy, CAC, MSNBC, Lung, Government, Anxiety, Pelvic floor dysfunction, Hill, Letter, Pharmaceutical industry

NEW YORK, April 22, 2024 /PRNewswire/ -- The Health Equity in Transplantation Coalition (HEiTC) and its partners are urging the federal government to address the discrepancy revealed by a Freedom of Information Act (FOIA) request: that the decision by Medicare contractors to limit coverage of blood tests blatantly contradicted the recommendations given by the government's own panel of medical experts. HEiTC's renewed call comes on the heels of a blistering Wall Street Journal editorial condemning the decision of the Medicare contractors to ignore the experts' recommendations. HEiTC continues to demand that Medicare contractors abolish ties to biopsies for coverage of these life-saving tests, which can detect a possible organ transplant rejections months before symptoms start to show.

Key Points: 
  • "Instead of listening to these experts and considering what these tests meant to tens of thousands of transplant recipients, the contractor not only ignored but withheld their expert opinion.
  • It's never been more important that these cutbacks are reversed and coverage without any tie to a biopsy is restored."
  • The new information shows that private Medicare contractors failed to disclose and then ignored the near-unanimous advice of expert physicians – handpicked by the contractors—to evaluate the evidence for non-invasive transplant rejection testing.
  • There was broad consensus from these expert clinicians that the testing had significant clinical utility including for routine, surveillance testing.

How a Social Media Post Led a Teen to Find a 'Kidney Buddy' for Life

Retrieved on: 
Thursday, April 18, 2024
Nephronophthisis, Kidney, Social media, BSN, News, Blood, Kidney failure, Jaxon, Thought, Lucile Packard Children's Hospital, Life, Friends, Disease, Los Angeles Dodgers, CCTC, Family, Transplant, Eye, Dialysis, Altruism, RN, PALO, Diagnosis, Orbital cellulitis, Genetic disorder, Infection, Nursing

Sarah called the number on the post, which led her to the transplant coordinators at Stanford Medicine Children's Health to begin the living donor screening process.

Key Points: 
  • Sarah called the number on the post, which led her to the transplant coordinators at Stanford Medicine Children's Health to begin the living donor screening process.
  • Jaxon was less than six months from requiring dialysis, said Thomas Pham, MD , pediatric kidney transplant surgical director at Stanford Children's.
  • She's also saving another life because it's making an organ available for someone else on the transplant list.
  • We're blessed to live in a time where we have Facebook, Instagram, and all of the other social media platforms."

Graceland Rehabilitation and Nursing Center First in Memphis to Receive Enhanced Respiratory Care Accreditation

Retrieved on: 
Thursday, April 18, 2024
Patient, Enhanced, American College, Mechanical ventilation, ACCS, Health, Friends, Patient safety, Accreditation, Nursing, Executive director, Dialysis, Weaning, AARC, Quality of life, Hospital

MEMPHIS, Tenn., April 18, 2024 /PRNewswire-PRWeb/ -- The Physician-Patient Alliance for Health & Safety (PPAHS) is pleased to announce that Graceland Rehabilitation and Nursing Center in Memphis, TN, is the first nursing facility in West Tennessee to achieve Enhanced Respiratory Care Accreditation.

Key Points: 
  • MEMPHIS, Tenn., April 18, 2024 /PRNewswire-PRWeb/ -- The Physician-Patient Alliance for Health & Safety (PPAHS) is pleased to announce that Graceland Rehabilitation and Nursing Center in Memphis, TN, is the first nursing facility in West Tennessee to achieve Enhanced Respiratory Care Accreditation.
  • our Enhanced Respiratory Care Accreditation demonstrates our commitment to providing the highest standard of respiratory care to our patients.
  • As well, our Enhanced Respiratory Care Accreditation demonstrates our commitment to providing the highest standard of respiratory care to our patients."
  • The Enhanced Respiratory Care Standards of Care are supported and endorsed by the American Association for Respiratory Care.

Alport Syndrome Market to Witness Upsurge in Growth at a Massive CAGR of 69% by 2034 | DelveInsight

Retrieved on: 
Wednesday, April 17, 2024
USD, Urine, ACE, Finerenone, ESRD, Kidney, Otorhinolaryngology, Nephrotoxicity, Mutation, Hearing, Diagnosis, Glomerular filtration rate, Hearing loss, Blood, Swelling, Proteinuria, Kidney failure, Cochlea, Alport syndrome, Nephrology, EU4, GFR, ADAS, Heredity, Research, Genetic counseling, Kidney disease, Novartis, ARAS, Ophthalmology, COL4A4, Patient, Kidney transplantation, LAS, Dialysis, DSM-IV codes, COL4A3, Quality of life, Genetic disorder, Gene, Pharmaceutical industry

LAS VEGAS, April 17, 2024 /PRNewswire/ -- DelveInsight's Alport Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, Alport syndrome emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Key Points: 
  • Leading Alport syndrome companies such as Eloxx Pharmaceuticals, Chinook Therapeutics (A Novartis company), Bayer, Calliditas Therapeutics, Evotec, and others are developing novel Alport syndrome drugs that can be available in the Alport syndrome market in the coming years.
  • The disorder manifests in different forms such as autosomal recessive Alport syndrome (ARAS), X-linked Alport syndrome (XLAS), and autosomal dominant Alport syndrome (ADAS).
  • The X-linked Alport syndrome (XLAS) is the most prevalent subtype of Alport syndrome with around 11K cases in 2023 in the US while autosomal dominant Alport syndrome (ADAS) is the least prevalent subtype of Alport syndrome.
  • To know more about Alport syndrome treatment guidelines, visit @ Alport Syndrome Management

Alport Syndrome Market to Witness Upsurge in Growth at a Massive CAGR of 69% by 2034 | DelveInsight

Retrieved on: 
Wednesday, April 17, 2024
USD, Urine, ACE, Finerenone, ESRD, Kidney, Otorhinolaryngology, Nephrotoxicity, Mutation, Hearing, Diagnosis, Glomerular filtration rate, Hearing loss, Blood, Swelling, Proteinuria, Kidney failure, Cochlea, Alport syndrome, Nephrology, EU4, GFR, ADAS, Heredity, Research, Genetic counseling, Kidney disease, Novartis, ARAS, Ophthalmology, COL4A4, Patient, Kidney transplantation, LAS, Dialysis, DSM-IV codes, COL4A3, Quality of life, Genetic disorder, Gene, Pharmaceutical industry

LAS VEGAS, April 17, 2024 /PRNewswire/ -- DelveInsight's Alport Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, Alport syndrome emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Key Points: 
  • Leading Alport syndrome companies such as Eloxx Pharmaceuticals, Chinook Therapeutics (A Novartis company), Bayer, Calliditas Therapeutics, Evotec, and others are developing novel Alport syndrome drugs that can be available in the Alport syndrome market in the coming years.
  • The disorder manifests in different forms such as autosomal recessive Alport syndrome (ARAS), X-linked Alport syndrome (XLAS), and autosomal dominant Alport syndrome (ADAS).
  • The X-linked Alport syndrome (XLAS) is the most prevalent subtype of Alport syndrome with around 11K cases in 2023 in the US while autosomal dominant Alport syndrome (ADAS) is the least prevalent subtype of Alport syndrome.
  • To know more about Alport syndrome treatment guidelines, visit @ Alport Syndrome Management

International Fellowship of Christians and Jews Mobilizes to Provide Emergency Aid in Response to Iranian Attacks

Retrieved on: 
Monday, April 15, 2024
NICU, Eckstein, Christians, Radio, Jews, Hospital, Risk, Emergency medicine, Hygiene, Dialysis, Hezbollah

JERUSALEM, April 15, 2024 /PRNewswire/ -- Following the attacks from Iran on April 13 in which hundreds of drones and missiles were launched at Israel from Iran and its proxies, The International Fellowship of Christians and Jews (The Fellowship) announced today it has taken immediate action to approve $600,000 for emergency food and shelter boxes. Additionally, the organization is expediting the production and placement of additional bomb shelters in the northern region of Israel—a project not originally planned until after Passover.

Key Points: 
  • "The Fellowship has been preparing for an escalation along the northern border of Israel since October 7, and we haven't stopped since," said Fellowship President and CEO, Yael Eckstein.
  • We continue to provide aid and security to the people of Israel, whether the attack is from Hamas, Hezbollah, or Iran.
  • As the agents of death try to wreak destruction, The Fellowship continues to invest in protection and sanctifying life."
  • Eckstein added, "No matter what the risk, the crisis, or the need—big or small—the Fellowship will always be there, as we have for more than 40 years."

Kidney Patients Honor Top Physician for Disease and Infection Prevention

Retrieved on: 
Monday, April 15, 2024
Education, FDA, Kidney disease, Medicine, Chronic kidney disease, Kidney, CDC, RPA, The Rogosin Institute, Society, Nursing, Optimism, Dialysis, Medal, Problem solving, Patient, NIH, Health, Nephrology, Research, World Neurosurgery, Retirement, CKD, Family, VHI, Medicare, Government, ESRD, Bangladesh Technical Education Board, Social work, Policy, MD, Renal Physicians Association, Science, Pharmaceutical industry

WASHINGTON, April 15, 2024 /PRNewswire/ -- The American Association of Kidney Patients (AAKP), America's oldest and largest independent kidney patient advocacy organization, awarded its 2024 Medal of Excellence Award in the Physician Category to Dr. Barry Smith, PhD, MD, President of New York-based Dreyfus Health Policy and Research Center. The AAKP announcement occurred during the 50th Anniversary Meeting of the Renal Physicians Association (RPA) in Baltimore, Maryland. 

Key Points: 
  • The RPA is a long-standing ally of the AAKP and is the professional organization of nephrologists whose goal is to ensure quality care under the highest standards of medical practice for patients with kidney disease and related disorders.
  • Dr. Smith was selected as a Physician Honoree based on his distinguished career spanning academia, government, and clinical care management and his dedicated efforts to expand patient engagement in infection prevention and medical innovation.
  • Dr. Smith is highly regarded for his focus on disease prevention through better community education on issues including food choices and nutrition as well infection prevention through improved safety measures and access to new safety innovations.
  • The Medal of Excellence includes award categories in transplant surgery, transplant professional, physician, nursing, dietitian, social work, and dialysis technician.

Healthcare M&A Volume Falls in Q1:24, According to Acquisition Data from LevinPro HC

Retrieved on: 
Friday, April 12, 2024
Housing, Laboratory, Novo Holdings A/S, Research, EHealth, Intelligence, CDMO, Catalent, Biotechnology, HC, Acquisition, Medicare, MRI, Hospice, Novo Nordisk Foundation, Dialysis, Pharmaceutical industry

NEW CANAAN, Conn., April 12, 2024 /PRNewswire-PRWeb/ --  Healthcare merger and acquisition activity declined by 4% in the first quarter of 2024, according to new acquisition data from LevinPro HC. Deal volume in Q1:24 only reached 494 deals, falling short of the 515 transactions announced in the fourth quarter of 2023. Year-over-year changes were even more pronounced, with an 11% decline in activity in Q1:24 compared with the first quarter of 2023, when 555 deals were announced.

Key Points: 
  • Healthcare merger and acquisition activity declined by 4% in the first quarter of 2024, according to new acquisition data from LevinPro HC.
  • Deal volume in Q1:24 only reached 494 deals, falling short of the 515 transactions announced in the fourth quarter of 2023.
  • NEW CANAAN, Conn., April 12, 2024 /PRNewswire-PRWeb/ --  Healthcare merger and acquisition activity declined by 4% in the first quarter of 2024, according to new acquisition data from LevinPro HC.
  • Deal volume in Q1:24 only reached 494 deals, falling short of the 515 transactions announced in the fourth quarter of 2023.